Mammalian Transient Protein Expression Market Aims for US$ 697.2 Million Valuation by 2033

The global mammalian transient protein expression market sale is predicted to develop at an 8.5% CAGR from 2023 to 2033, according to FMI’s most recent market research. In 2023, the market is expected to be worth US$ 697.2 million. By 2033, it is projected that the valuation will amount to US$ 1,581.6 million.

Revenue-wise, the Mammalian Transient Protein Expression industry is probably going to increase significantly. The market for mammalian cells used for protein expression is likewise growing as a result of rising industry spending on R&D and technological developments that allow for more accurate and efficient protein production. However, the creation of new technologies is making it simpler to employ mammalian cells for protein expression as therapeutic agents.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-12807

The growing market for Mammalian Transient Protein Expression includes a significant portion devoted to the expression of transitory proteins in mammals. Companies use this technology to create functional proteins, polypeptides, and other molecules.

Key Takeaways:

  • The introduction of new delivery systems, such as nanotechnology and drug-delivery vehicles, is likely to be the significant driver of the market.
  • The global Mammalian Transient Protein Expression is expected to hold a valuation of US$ 697.2 million in 2023.
  • The global Mammalian Transient Protein Expression market is expected to surpass US$ 1,581.6 million by 2033.
  • The Mammalian Transient Protein Expression market is likely to record a CAGR of 8.5% from 2023 to 2033.
  • The biopharmaceutical companies segment recorded a CAGR of 9.8% from 2018 to 2022 and is expected to record a CAGR of 9.1% from 2023 to 2033.
  • The Mammalian Transient Protein Expression market in China is likely to record a CAGR of 9.0% over the forecast period.
  • The reagents and consumables segment recorded a CAGR of 10.6% from 2018 to 2022 and is expected to register a CAGR of 9.6% from 2023 to 2033.

Competitive Landscape

The key players operating in the Mammalian Transient Protein Expression market are investing in mergers and acquisitions to gain a significant market share. The manufacturers are also investing in research and development and are introducing innovative methods to boost production capacity. Product development and market expansion are significant aspects of the Mammalian Transient Protein Expression market. As a result, market participants are likely to have a better overall revenue share in the global Mammalian Transient Protein Expression market.

Recent Developments:

  • In October 2020, Merck KgaA announced its expansion, which included the opening of a new membrane manufacturing facility in Darmstadt, Germany. Increasing the output of Millipore Express membranes was the objective.
  • Thermo Fisher Scientific introduced the GMP-produced Gibco CTS TrueCut Cas9 Protein in April 2022.

Significant Key Players are:

  1. Thermofisher Scientific
  2. Merck KGaA
  3. Promega Corporation
  4. Lonza
  5. Agilent Technologies, Inc.
  6. Bio-Rad
  7. Qiagen
  8. Takara Bio
  9. HiMedia Laboratories.
  10. Mirus
  11. Sino Biological, Inc.

Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-12807

Key Segments:

By Product:

  • Instruments
  • Expression Vector
  • Reagents & Consumables
  • Cell Lines
    • Chinese Hamster Ovary Cells (CHO)
    • Human embryonic kidney 293 (HEK 293) cells
    • Others

By Application:

  • Bio-production
    • Antibody Production
    • Therapeutic protein production
  • Functional Cell-Based Assays
  • Academic Research
  • Others

By End User:

  • Contract Research Organization
  • Biopharmaceutical Companies
  • Academic & Research Institutes

Related Post